HomeCompareSLRN vs PM

SLRN vs PM: Dividend Comparison 2026

SLRN yields 88.11% · PM yields 3.49%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SLRN wins by $2.32M in total portfolio value
10 years
SLRN
SLRN
● Live price
88.11%
Share price
$2.27
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.37M
Annual income
$731,873.50
Full SLRN calculator →
PM
Philip Morris International
● Live price
3.49%
Share price
$164.83
Annual div
$5.76
5Y div CAGR
17.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$2,502.61
Full PM calculator →

Portfolio growth — SLRN vs PM

📍 SLRN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSLRNPM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SLRN + PM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SLRN pays
PM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SLRN
Annual income on $10K today (after 15% tax)
$7,488.99/yr
After 10yr DRIP, annual income (after tax)
$622,092.48/yr
PM
Annual income on $10K today (after 15% tax)
$297.03/yr
After 10yr DRIP, annual income (after tax)
$2,127.22/yr
At 15% tax rate, SLRN beats the other by $619,965.26/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SLRN + PM for your $10,000?

SLRN: 50%PM: 50%
100% PM50/50100% SLRN
Portfolio after 10yr
$1.21M
Annual income
$367,188.06/yr
Blended yield
30.40%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PM right now

SLRN
Analyst Ratings
3
Buy
3
Hold
Consensus: Buy
Price Target
$10.50
+362.6% upside vs current
Range: $6.00 — $15.00
Altman Z
1.6
Piotroski
2/9
PM
Analyst Ratings
17
Buy
7
Hold
1
Sell
Consensus: Buy
Price Target
$194.30
+17.9% upside vs current
Range: $180.00 — $205.00
Altman Z
4.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SLRN buys
0
PM buys
0
No recent congressional trades found for SLRN or PM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSLRNPM
Forward yield88.11%3.49%
Annual dividend / share$2.00$5.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17.2%
Portfolio after 10y$2.37M$49.6K
Annual income after 10y$731,873.50$2,502.61
Total dividends collected$2.08M$11.8K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy
Analyst price target$10.50$194.30

Year-by-year: SLRN vs PM ($10,000, DRIP)

YearSLRN PortfolioSLRN Income/yrPM PortfolioPM Income/yrGap
1← crossover$19,511$8,810.57$11,650$409.56+$7.9KSLRN
2$36,942$16,065.36$13,592$497.49+$23.4KSLRN
3$67,956$28,428.44$15,882$605.21+$52.1KSLRN
4$121,587$48,874.33$18,589$737.41+$103.0KSLRN
5$211,824$81,725.42$21,794$899.94+$190.0KSLRN
6$359,715$133,063.84$25,597$1,100.16+$334.1KSLRN
7$596,079$211,183.71$30,118$1,347.30+$566.0KSLRN
8$964,860$327,055.60$35,505$1,652.97+$929.4KSLRN
9$1,527,165$494,764.27$41,940$2,031.88+$1.49MSLRN
10$2,365,940$731,873.50$49,643$2,502.61+$2.32MSLRN

SLRN vs PM: Complete Analysis 2026

SLRNStock

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.

Full SLRN Calculator →

PMConsumer Staples

Philip Morris International Inc. operates as a tobacco company working to delivers a smoke-free future and evolving portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company's product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products that are sold in markets outside the United States. The company offers its smoke-free products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, Parliament HeatSticks, and TEREA brands, as well as the KT&G-licensed brands, Fiit, and Miix. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. The company sells its smoke-free products in 71 markets. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.

Full PM Calculator →
📬

Get this SLRN vs PM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SLRN vs SCHDSLRN vs JEPISLRN vs OSLRN vs KOSLRN vs MAINSLRN vs MOSLRN vs BTISLRN vs PEP

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.